The significance of ADAMTSI3 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 599-600

  Shimizu, Michiomi ^a   Nomura, Shosaku ^a   Ishii, Kazuyoshi ^a   Mohri, Youichi ^a   Umei, Nao ^a   Suzuki, Satoshi ^a   Matsuo, Yoshio ^a   Isonishi, Ayami ^b   Matsumoto, Masanori ^b   Urase, Fumiaki ^c   Maeda, Yasuhiro ^c   Fujimura, Yoshihiro ^b  

^a Kishiwada City Hospital   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; CASE REPORT; CORTICOSTEROID THERAPY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; DRUG ANTAGONISM; IMMUNOLOGY; LETTER; MIDDLE AGED;

ADAM PROTEINS; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 62549133537     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0606     Document Type: Article

References (13)

1. Moschowitz E, Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Sac 1924: 24: 21-24.
2. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
3. Hagel S, Jantseh J, Budde U, et al. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab, Thromb Haemost 2008; 100: 151-153.
4. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor (vWF) cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-1063.
5. Luken BM, Turenhout EA, Hulstein JJ, et al. The space domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 267-274.
6. Luken BM, Turenhout EA, Kaijen PH, et al. Aminoacid regions 572-579 and 657-666 of the spacer domain of AMATS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96: 295-301.
7. Donadelli R, Banteria F. Galbusera M, et al. Invitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96: 454-464.
8. Hommais A, Rayes J, Houllier A, et al. Molecular characterization of four ADAMTS 13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Thromb Haemost 2007; 98: 593-599.
9. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS 13 to the stellate cells of Iranian liver. Blood 2005; 106: 922-924.
10. Uemura M, FujimuraY, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
11. Czaja AX Autoimmune hepatitis: evolving concepts and treatment strategies. Deg Dis Sci 1995; 40: 435-438.
12. Alvarez F, Berg PA, Bianch FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
13. Shibuya A, Satomichi A, Nagaba S, et al. Thrombotic thrombocytopenic purpura in autoimmune hepatitis. J Gastroenterol 2001; 36: 569-573.